Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
302.15(c) 300.55(c) 300.15(c) 303.1(c) 302.5(c) Last
2 314 169 3 319 931 2 564 685 1 624 983 2 015 268 Volume
-0.84% -0.53% -0.13% +0.98% -0.20% Change
More quotes
Financials
Sales 2020 59 977 M 66 287 M 66 287 M
Net income 2020 14 353 M 15 863 M 15 863 M
Net cash position 2020 3 530 M 3 901 M 3 901 M
P/E ratio 2020 18,3x
Yield 2020 3,07%
Sales 2021 62 782 M 69 387 M 69 387 M
Net income 2021 15 560 M 17 197 M 17 197 M
Net cash position 2021 11 571 M 12 788 M 12 788 M
P/E ratio 2021 16,7x
Yield 2021 3,18%
Capitalization 259 B 286 B 286 B
EV / Sales 2020 4,25x
EV / Sales 2021 3,94x
Nbr of Employees 97 735
Free-Float 83,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
12/02Präsentation
More about the company
All news about ROCHE HOLDING AG
11/26Business rights or human rights? Swiss vote shines spotlight on companies
RE
11/25Chugai and DeNA Jointly Launch 'Ring Again,' a Rheumatoid Arthritis Disease A..
AQ
11/25SHIONOGI : Announces FDA Approval of XOFLUZA for the prevention of Influenza fol..
AQ
11/24GLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
11/24ROCHE : Genentech Announces FDA Approval of Xofluza for the Prevention of Influe..
AQ
11/24ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..
PU
11/24ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..
PU
11/24ROCHE : announces FDA approval of Xofluza for the prevention of influenza follow..
AQ
11/23GENENTECH : Announces FDA Approval of Xofluza for the Prevention of Influenza Fo..
BU
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
RE
11/23ROCHE : Regeneron's REGN-COV2 is first antibody cocktail for COVID-19 to receive..
PU
11/20CHUGAI PHARMACEUTICAL : Receives the Best IR Award
AQ
11/19ROCHE : Actemra helps the sickest COVID-19 patients, study shows
RE
11/18CHUGAI PHARMACEUTICAL : Selected for the First Time in the 'DJSI World,' a Globa..
AQ
11/17Companies Battle Cybersecurity Risks of Having More Remote Workers -- Journal..
DJ
More news
News in other languages on ROCHE HOLDING AG
11/27Aktien Schweiz weiterhin lust- und Impulslos
11/27ROCHE : en repli, un analyste abaisse son objectif
11/27Ikea-Erben bleiben reichste Familie in der Schweiz
11/26Aktien Schweiz bewegen sich weiter seitwärts
11/24EN DIRECT DES MARCHES : Total, JCDecaux, Neoen, Quadient, Tesla, Novartis, Gener..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 08/19
Close to an important medium term support level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 375,80 CHF
Last Close Price 302,50 CHF
Spread / Highest target 44,1%
Spread / Average Target 24,2%
Spread / Lowest Target -5,79%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-3.66%285 972
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440